Teva Pharmaceutical Industries (TEVA) Non-Current Assets (2009 - 2026)
Teva Pharmaceutical Industries' (TEVA) quarterly Non-Current Assets came in at $26.1 billion in Q2 2026, down 5.14% YoY from $27.5 billion in Q2 2025, and down 0.88% on a QoQ basis from $26.3 billion in Q1 2026.
Teva Pharmaceutical Industries (TEVA) Non-Current Assets (2009 - 2026) Analysis & Trends
Teva Pharmaceutical Industries (TEVA) has 18 years of Non-Current Assets data on file, last reported at $26.1 billion in Q2 2026.
- Quarterly Non-Current Assets fell 5.14% year-over-year to $26.1 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $106.3 billion (down 3.86% YoY) and the FY2025 annual result came in at $26.8 billion, changed 0.1% from the prior year.
- Non-Current Assets slipped to $26.1 billion in Q2 2026, from $26.3 billion in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $34.6 billion in Q1 2022 to a low of $26.1 billion in Q2 2026.
- A 5-year average of $29.7 billion and a median of $30.1 billion in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2024 — Non-Current Assets fell 13.62% — and 2025, when it advanced 0.1%.
- Tracing TEVA's Non-Current Assets over 5 years: stood at $32.0 billion in 2022, then dropped by 3.02% to $31.0 billion in 2023, then slipped by 13.62% to $26.8 billion in 2024, then increased by 0.1% to $26.8 billion in 2025, then decreased by 2.63% to $26.1 billion in 2026.
- The last three Non-Current Assets figures came in at $26.1 billion (Q2 2026), $26.3 billion (Q1 2026), and $26.8 billion (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.65 Bn | 42.68 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 43.09 Bn | 39.44 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.11 Bn | 19.45 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.77 Bn | 17.88 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 12.07 Bn | 11.54 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.09 Bn | 9.93 Bn | - | 2.96 Bn |
| 10 | Alkermes | 8.20 Bn | 7.54 Bn | 397.90 Mn | 2.87 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26.10 Bn |
| Mar 31, 2026 | 26.33 Bn |
| Dec 31, 2025 | 26.80 Bn |
| Sep 30, 2025 | 27.12 Bn |
| Jun 30, 2025 | 27.51 Bn |
| Mar 31, 2025 | 26.89 Bn |
| Dec 31, 2024 | 26.77 Bn |
| Sep 30, 2024 | 29.44 Bn |
| Jun 30, 2024 | 29.71 Bn |
| Mar 31, 2024 | 30.48 Bn |
| Dec 31, 2023 | 30.99 Bn |
| Sep 30, 2023 | 30.67 Bn |
| Jun 30, 2023 | 31.01 Bn |
| Mar 31, 2023 | 31.96 Bn |
| Dec 31, 2022 | 31.96 Bn |
| Sep 30, 2022 | 32.80 Bn |
| Jun 30, 2022 | 33.77 Bn |
| Mar 31, 2022 | 34.61 Bn |
| Dec 31, 2021 | 35.09 Bn |
| Sep 30, 2021 | 35.70 Bn |